Investigation of the intermolecular recognition mechanism between the E3 ubiquitin ligase Keap1 and substrate based on multiple substrates analysis

E3 ubiquitin ligases are attractive drug targets due to their specificity to the ubiquitin machinery. However, the development of E3 ligase inhibitors has proven challenging for the fact that they must disrupt protein–protein interactions (PPIs). The E3 ligase involved in interactome provide new hope for the discovery of the E3 ligase inhibitors. These currently known natural binding partners of the E3 ligase can benefit the discovery of other unknown substrates and also the E3 ligase inhibitors. Herein, we present a novel strategy that using multiple substrates to elucidate the molecular recognition mechanism of E3 ubiquitin ligase. Molecular dynamics simulation, molecular mechanics-generalized born surface area (MM-GBSA) binding energy calculation and energy decomposition scheme were incorporated to evaluate the quantitative contributions of sub-pocket and per-residue to binding. In this case, Kelch-like ECH-associated protein-1 (Keap1), a substrate adaptor component of the Cullin–RING ubiquitin ligases complex, is applied for the investigation of how it recognize its substrates, especially Nrf2, a master regulator of the antioxidant response. By analyzing multiple substrates binding determinants, we found that both the polar sub-pockets (P1 and P2) and the nonpolar sub-pockets (P4 and P5) of Keap1 can make remarkable contributions to intermolecular interactions. This finding stresses the requirement for substrates to interact with the polar and nonpolar sub-pockets simultaneously. The results discussed in this paper not only show the binding determinants of the Keap1 substrates but also provide valuable implications for both Keap1 substrate discovery and PPI inhibitor design.

[1]  Kristiina Takkinen,et al.  Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. , 2008 .

[2]  Tsutomu Ohta,et al.  Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. , 2006, Molecular cell.

[3]  J. Hayes,et al.  Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction. , 2012, Free radical biology & medicine.

[4]  P. Kollman,et al.  Molecular Dynamics Simulations on Solvated Biomolecular Systems: The Particle Mesh Ewald Method Leads to Stable Trajectories of DNA, RNA, and Proteins , 1995 .

[5]  E. White,et al.  Arsenic Inhibits Autophagic Flux, Activating the Nrf2-Keap1 Pathway in a p62-Dependent Manner , 2013, Molecular and Cellular Biology.

[6]  J. D. Engel,et al.  Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Harper,et al.  Inhibitors for E3 ubiquitin ligases , 2010, Nature Biotechnology.

[8]  Longqin Hu,et al.  Small Molecule Modulators of Keap1‐Nrf2‐ARE Pathway as Potential Preventive and Therapeutic Agents , 2012, Medicinal research reviews.

[9]  Ken Garber,et al.  Missing the target: ubiquitin ligase drugs stall. , 2005, Journal of the National Cancer Institute.

[10]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[11]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[12]  S. Niture,et al.  INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis , 2011, Cell Death and Differentiation.

[13]  Garrett M. Morris,et al.  Molecular Determinants of Binding to the Plasmodium Subtilisin-like Protease 1 , 2013, J. Chem. Inf. Model..

[14]  W. L. Jorgensen,et al.  Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. , 2012, Angewandte Chemie.

[15]  Q. You,et al.  Insight into the Intermolecular Recognition Mechanism between Keap1 and IKKβ Combining Homology Modelling, Protein-Protein Docking, Molecular Dynamics Simulations and Virtual Alanine Mutation , 2013, PloS one.

[16]  S. Yokoyama,et al.  Structural analysis of the complex of Keap1 with a prothymosin alpha peptide. , 2008, Acta crystallographica. Section F, Structural biology and crystallization communications.

[17]  Y. Li,et al.  Chemical genetics of TOR identifies an SCF family E3 ubiquitin ligase inhibitor , 2010, Nature Biotechnology.

[18]  M. Hung,et al.  KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. , 2009, Molecular cell.

[19]  Akira Kobayashi,et al.  Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism , 2006, Biological chemistry.

[20]  D. Ecker,et al.  A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. , 1989, Science.

[21]  A. Weissman.  Ubiquitin and proteasomes: Themes and variations on ubiquitylation , 2001, Nature Reviews Molecular Cell Biology.

[22]  P. Cohen,et al.  Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases? , 2010, Cell.

[23]  T. Mizushima,et al.  Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. , 2013, Molecular cell.

[24]  S. Hirohashi,et al.  Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. , 2008, Cancer research.

[25]  S. Yokoyama,et al.  Different Electrostatic Potentials Define ETGE and DLG Motifs as Hinge and Latch in Oxidative Stress Response , 2007, Molecular and Cellular Biology.

[26]  Su Qiu,et al.  Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. , 2010, Journal of medicinal chemistry.

[27]  T. Ogura,et al.  Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains , 2010, Proceedings of the National Academy of Sciences.

[28]  Nadine H. Elowe,et al.  An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase , 2010, Nature Biotechnology.

[29]  Holger Gohlke,et al.  Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..

[30]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[31]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[32]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.

[33]  Martin Rechsteiner,et al.  Recognition of the polyubiquitin proteolytic signal , 2000, The EMBO journal.

[34]  Q. You,et al.  Novel protein–protein interaction inhibitor of Nrf2–Keap1 discovered by structure-based virtual screening , 2014 .

[35]  Q. You,et al.  Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. , 2014, Journal of medicinal chemistry.

[36]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[37]  A. Brik,et al.  Chemistry and biology of the ubiquitin signal. , 2012, Angewandte Chemie.

[38]  M. Sporn,et al.  NRF2 and cancer: the good, the bad and the importance of context , 2012, Nature Reviews Cancer.

[39]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[40]  Julien Michel,et al.  Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction , 2012, Journal of the American Chemical Society.

[41]  A. Roitberg,et al.  All-atom structure prediction and folding simulations of a stable protein. , 2002, Journal of the American Chemical Society.

[42]  M. Rapé,et al.  The Ubiquitin Code , 2012, Annual review of biochemistry.

[43]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[44]  Mihee M. Kim,et al.  The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1 , 2010, Nature Cell Biology.

[45]  K. Itoh,et al.  Keap1 Recruits Neh2 through Binding to ETGE and DLG Motifs: Characterization of the Two-Site Molecular Recognition Model , 2006, Molecular and Cellular Biology.

[46]  N. Gray,et al.  Small molecule modulators of antioxidant response pathway. , 2011, Current opinion in chemical biology.

[47]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[48]  M. Sonobe,et al.  Mutations in Keap1 are a potential prognostic factor in resected non‐small cell lung cancer , 2010, Journal of surgical oncology.

[49]  R. Deshaies,et al.  RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.